PSUR and PBRER: Periodic Safety Reporting Without the Confusion

These two terms are used interchangeably and are not quite the same thing, which causes more confusion than it should.

PBRER is the Periodic Benefit-Risk Evaluation Report, the format defined by ICH E2C(R2).

PSUR is the Periodic Safety Update Report, which is what EU legislation calls the report a marketing authorisation holder must submit. Since E2C(R2), the EU PSUR is submitted in the PBRER format.

So: PBRER is the format, PSUR is the EU regulatory obligation that uses it. In conversation people say PSUR and mean both.

What the report is for

It is a periodic reassessment of whether the benefit-risk balance of a marketed product still holds, in light of everything learned since the last one.

That framing is the substance of the R2 change. The earlier PSUR was safety-focused: here is what happened. The PBRER asks a harder question: given what happened, is this product still worth using, and does anything need to change.

The two dates that govern everything

International Birth Date (IBD). The date of the first marketing authorisation for the product anywhere in the world. Reporting periodicity is anchored to it, which means a product first approved in a small market carries that date globally.

Data Lock Point (DLP). The cut-off date for data included in the report. Everything up to the DLP is in scope; everything after waits for the next one.

Submission is due within a set period after the DLP: 70 days for reporting intervals of 12 months or less, 90 days for longer intervals.

The consequence people underestimate is that the DLP is not a deadline you can move. Work backwards from it, because line listings, signal evaluation and the benefit-risk discussion all have to happen inside a fixed window after the data closes.

What it contains

Beyond the safety data:

• Estimated exposure, from sales or prescription data. A rate needs a denominator.
• Summaries of significant findings from clinical trials, non-interventional studies, and the literature during the interval.
• Signal evaluation: signals identified, evaluated, and their outcomes, which connects directly to signal detection practice.
• Benefit evaluation and an integrated benefit-risk analysis.
• Actions taken for safety reasons, and changes to the reference product information.

Where it goes wrong

The schedule is missed because periodicity changed. The EU publishes the EURD list, which sets DLPs and frequencies for substances, and it overrides what the authorisation originally said. A holder still working from the original schedule is late without knowing.

The report contradicts the label. A PBRER describing a risk the CCDS does not reflect raises the obvious question of why the label was not updated.

Exposure data is soft. Benefit-risk is a rate argument, and a weak denominator undermines it.